Phase 2 Trial of Levosimendan to Treat PH Linked to Specific Heart Failure Moving Forward
Plans for a Phase 2 clinical trial of levosimendan, a proposed treatment for pulmonary hypertension associated with heart failure and preserved ejection fraction, will soon be submitted to the U.S. Food and Drug Administration for approval, Tenax Therapeutics announced. In a pre-application meeting with company executives, the FDA supported the study’s proposed…